SEC Comment Letter for Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Jan 24, 2020
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: Jan. 24, 2020 · CIK: 0001430306 · Accession: 0000000000-20-000663
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235976
Letter
January 24, 2020 Seth Lederman Chief Executive Officer Tonix Pharmaceuticals Holding Corp. 509 Madison Avenue, Suite 1608 New York, NY 10022 Re:Tonix Pharmaceuticals Holding Corp. Registration Statement on From S-1 Filed January 21, 2020 File No. 333-235976 Dear Mr. Lederman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael J. Lerner, Esq.
Show Raw Text
January 24, 2020
Seth Lederman
Chief Executive Officer
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 1608
New York, NY 10022
Re:Tonix Pharmaceuticals Holding Corp.
Registration Statement on From S-1
Filed January 21, 2020
File No. 333-235976
Dear Mr. Lederman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael J. Lerner, Esq.